drugset / Trial / NCT02828397
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
RandomizedParallel-groupOpen-labelBasic science
Summary
Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222
Timeline
- Start
- 2016-04
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suptavumab | Monoclonal antibody | — | Intramuscular |
Indications
No indication recorded.